Literature DB >> 9765130

The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism.

G Rozas1, E López-Martín, M J Guerra, J L Labandeira-García.   

Abstract

We investigated the usefulness of the Overall Rotarod Performance (ORP) test for evaluating overall locomotory ability in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-injected-mouse model of Parkinson's disease (PD). For this procedure, the mice are pretrained on the rotarod and then tested at a series of increasing speeds, recording the time that the animal remains on the rod at each speed; the overall rod performance (ORP) of each animal is then calculated as the area under the curve in a plot of time-on-the-rod against rotation speed. At 15-day intervals, C57BL/6 mice were injected (or sham-injected) with MPTP, with ORP testing 7-10 days after each injection. After the fourth injection (day 45), mice in the treated group showed clearly lower ORP than mice in the control group (70-90% reduction in ORP), and were thus considered effectively lesioned. Subsequently, we investigated the short-term effects of apomorphine and L-DOPA on ORP in MPTP-treated mice. Apomorphine (at 0.5 or 2.5 mg/kg) had no significant effect, while L-DOPA (at 80 but not at 40 mg/kg) caused almost complete short-term recovery of pretreatment ORP. By about 100 days after the last MPTP injection, MPTP-treated mice showed partial long-term recovery of ORP; at this stage the mice were killed for tyrosine hydroxylase (TH) immunohistochemistry studies. TH immunoreactivity in the striatum showed a strong positive correlation with ORP as tested on day 100. We conclude that the ORP test is useful for evaluating motor deficit in MPTP-treated mice, and the effects of subsequent treatments.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765130     DOI: 10.1016/s0165-0270(98)00078-8

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  63 in total

1.  Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease.

Authors:  Eleni Antzoulatos; Michael W Jakowec; Giselle M Petzinger; Ruth I Wood
Journal:  Pharmacol Biochem Behav       Date:  2010-03-27       Impact factor: 3.533

2.  WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  David A Price; Alex A Martinez; Alexandre Seillier; Wouter Koek; Yolanda Acosta; Elizabeth Fernandez; Randy Strong; Beat Lutz; Giovanni Marsicano; James L Roberts; Andrea Giuffrida
Journal:  Eur J Neurosci       Date:  2009-05-21       Impact factor: 3.386

3.  Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse.

Authors:  Lori M Gorton; Marta G Vuckovic; Nina Vertelkina; Giselle M Petzinger; Michael W Jakowec; Ruth I Wood
Journal:  Behav Brain Res       Date:  2010-05-21       Impact factor: 3.332

4.  Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease.

Authors:  Alexandra Isabel Rosa; Sara Duarte-Silva; Anabela Silva-Fernandes; Maria João Nunes; Andreia Neves Carvalho; Elsa Rodrigues; Maria João Gama; Cecília Maria Pereira Rodrigues; Patrícia Maciel; Margarida Castro-Caldas
Journal:  Mol Neurobiol       Date:  2018-04-12       Impact factor: 5.590

5.  Dopamine neuron dependent behaviors mediated by glutamate cotransmission.

Authors:  Susana Mingote; Nao Chuhma; Abigail Kalmbach; Gretchen M Thomsen; Yvonne Wang; Andra Mihali; Caroline Sferrazza; Ilana Zucker-Scharff; Anna-Claire Siena; Martha G Welch; José Lizardi-Ortiz; David Sulzer; Holly Moore; Inna Gaisler-Salomon; Stephen Rayport
Journal:  Elife       Date:  2017-07-13       Impact factor: 8.140

6.  A disruption mechanism of the molecular clock in a MPTP mouse model of Parkinson's disease.

Authors:  Akane Hayashi; Naoya Matsunaga; Hiroyuki Okazaki; Keisuke Kakimoto; Yoshinori Kimura; Hiroki Azuma; Eriko Ikeda; Takeshi Shiba; Mayumi Yamato; Ken-Ichi Yamada; Satoru Koyanagi; Shigehiro Ohdo
Journal:  Neuromolecular Med       Date:  2013-01-05       Impact factor: 3.843

Review 7.  Neurobehavioural Changes in a Hemiparkinsonian Rat Model Induced by Rotenone.

Authors:  Sukala Puthuparambil Maniyath; Narayanan Solaiappan; Muthusamy Rathinasamy
Journal:  J Clin Diagn Res       Date:  2017-03-01

8.  D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease.

Authors:  Kim Tieu; Celine Perier; Casper Caspersen; Peter Teismann; Du-Chu Wu; Shi-Du Yan; Ali Naini; Miquel Vila; Vernice Jackson-Lewis; Ravichandran Ramasamy; Serge Przedborski
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

9.  Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease.

Authors:  R K Schwarting; M Sedelis; K Hofele; G W Auburger; J P Huston
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

Review 10.  Does the difference between physically active and couch potato lie in the dopamine system?

Authors:  Amy M Knab; J Timothy Lightfoot
Journal:  Int J Biol Sci       Date:  2010-03-09       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.